Evidence map›Paper›PMID 36612112›Full record

ReviewCancers2022

The Effects of Radioligand Therapy on Quality of Life and Sexual Function in Patients with Neuroendocrine Neoplasms.

Pasqualino Malandrino, Rossella Mazzilli, Giulia Puliani, Sergio Di Molfetta, Gabriella Pugliese, Soraya Olana, Anna Maria Colao, Antongiulio Faggiano, On Behalf Of The Nike Group

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Pasqualino MalandrinoEndocrinology Unit, Department of Clinical and Experimental Medicine, University of Catania and Garibaldi-Nesima Medical Center, 95122 Catania, Italy.ORCID 0000-0003-2474-0954
Rossella MazzilliEndocrinology Unit, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Sapienza University of Rome, ENETS Center of Excellence, 00189 Rome, Italy.
Giulia PulianiDepartment of Experimental Medicine, Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0003-2899-9146
Sergio Di MolfettaSection of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, 70124 Bari, Italy.ORCID 0000-0003-3454-7330
Gabriella PuglieseEndocrinology Unit, Department of Clinical Medicine and Surgery, Federico II University, 80131 Naples, Italy.
Soraya OlanaEndocrinology Unit, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Sapienza University of Rome, ENETS Center of Excellence, 00189 Rome, Italy.
Anna Maria ColaoEndocrinology Unit, Department of Clinical Medicine and Surgery, Federico II University, 80131 Naples, Italy.
Antongiulio FaggianoEndocrinology Unit, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Sapienza University of Rome, ENETS Center of Excellence, 00189 Rome, Italy.ORCID 0000-0002-9324-3946
On Behalf Of The Nike Group
Azienda Ospedaliera Sant'Andrea · ITFederico II University Hospital · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Bari Aldo Moro · ITUniversity of Catania · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peptide receptor radionuclide therapy (PRRT), also called radioligand therapy, is an effective antitumoral treatment in patients with neuroendocrine neoplasm (NEN). It improves the patient's health-related quality of life (HRQoL), which is evaluated by self-assessment questionnaires. The aim of this narrative review was to report the current knowledge on the changes of HRQoL and sexual function in patients with NEN treated with PRRT. We conducted a literature search of the PubMed, Embase, and APA PsycInfo databases. We selected 15 studies (12 for HRQoL and three for sexual function). After treatment with PRRT, patients with NEN experienced a significant improvement in their global health status, disease-related worries, social and emotional functioning, and cancer-related symptoms such as fatigue and diarrhea. Other symptoms, such as nausea/vomiting, dyspnea, and constipation, as well as the economic impact, were unchanged by radioligand therapy. Data on sexual function were not equally promising; only a few studies investigated this issue by using appropriate questionnaires in patients treated with radioligand therapy. Therefore, additional studies are needed to draw a conclusion about the benefits from PRRT on sexual function.

Indexed as

health-related quality of lifeneuroendocrine neoplasmpeptide receptor radionuclide therapyquestionnaireradioligand therapysexual function

Identifiers

PMID36612112
PMCPMC9817532
OpenAlexW4313414766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.